Retention of clinical biosamples / blank matrices [Regulatives / Guidelines]

posted by Ohlbe – France, 2019-04-24 11:54 (522 d 20:51 ago) – Posting: # 20219
Views: 1,742

Hi John,

» Do you know why some sponsors want to have their samples kept until application approved?

"Because we've always done it", I guess...

» From EMA or FDA, is there a requirement mentioned in any of the guidances?

EMA: no. FDA: not that I know of.

» We are doing this (store samples) as well and I wonder why we need to if the age of the samples exceeds the long term stability date.

I agree with ElMaestro: some sponsors just want to be on the safe side and only repeat the bioanalytical part rather than the whole study if the lab messed up somewhere. There was a time also when guidelines or requirements were not as clear as they can be now and an Agency would unexpectedly ask for the metabolite in addition to the parent, or similar stuff.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,081 posts in 4,397 threads, 1,468 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time: Monday 08:45 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5